ANL vs. ALT, ATXS, PAHC, ANAB, ABUS, CMPS, OCS, APLT, ORIC, and CVAC
Should you be buying Adlai Nortye stock or one of its competitors? The main competitors of Adlai Nortye include Altimmune (ALT), Astria Therapeutics (ATXS), Phibro Animal Health (PAHC), AnaptysBio (ANAB), Arbutus Biopharma (ABUS), COMPASS Pathways (CMPS), Oculis (OCS), Applied Therapeutics (APLT), ORIC Pharmaceuticals (ORIC), and CureVac (CVAC). These companies are all part of the "pharmaceutical preparations" industry.
Adlai Nortye (NASDAQ:ANL) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and community ranking.
Adlai Nortye has a net margin of 0.00% compared to Altimmune's net margin of -20,780.75%. Adlai Nortye's return on equity of 0.00% beat Altimmune's return on equity.
Adlai Nortye has higher earnings, but lower revenue than Altimmune.
35.2% of Adlai Nortye shares are held by institutional investors. Comparatively, 78.1% of Altimmune shares are held by institutional investors. 4.1% of Altimmune shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Altimmune had 5 more articles in the media than Adlai Nortye. MarketBeat recorded 11 mentions for Altimmune and 6 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 0.80 beat Altimmune's score of 0.07 indicating that Adlai Nortye is being referred to more favorably in the media.
Adlai Nortye currently has a consensus price target of $30.00, indicating a potential upside of 117.39%. Altimmune has a consensus price target of $15.00, indicating a potential upside of 129.01%. Given Altimmune's higher possible upside, analysts plainly believe Altimmune is more favorable than Adlai Nortye.
Altimmune received 43 more outperform votes than Adlai Nortye when rated by MarketBeat users. However, 100.00% of users gave Adlai Nortye an outperform vote while only 69.12% of users gave Altimmune an outperform vote.
Summary
Altimmune beats Adlai Nortye on 7 of the 13 factors compared between the two stocks.
Get Adlai Nortye News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adlai Nortye Competitors List
Related Companies and Tools
